PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance

Stage II Prostate Adenocarcinoma AJCC v7 Clinical Trial

Official title:

Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients With Clinically Localized Prostate Cancer Undergoing Active Surveillance

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02326805
• Other study ID #: NCI-2014-02556
• Secondary ID: NCI-2014-02556AZ
• Status: Completed
• Phase: Phase 2
• Start date: June 3, 2015
• Est. completion date: July 20, 2022

Study information

• Verified date: June 2023
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized phase II trial studies how well PROSTVAC (prostate-specific antigen [PSA]-TRICOM) works in preventing disease progression in patients with prostate cancer undergoing active surveillance. Vaccines made from a person's tumor cells may help the body build an effective immune response to kill tumor cells that express PSA.

Description:

PRIMARY OBJECTIVES: I. To determine the effect of rilimogene-galvacirepvec (PROSTVAC) on the change (from pre to post-intervention) in CD8+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies. II. To determine the effect of PROSTVAC on the change in CD4+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies. SECONDARY OBJECTIVES: I. To assess the effect of PROSTVAC on PD-L1 positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies. II. To assess the correlation between the change in CD8+ and the change in PSA. III. To assess the effect of PROSTVAC on CD8+, CD4+, and PD-L1 positive cells in the benign portion of the prostate biopsies. IV. To assess the effect of PROSTVAC on the change in PSA. V. To assess the effect of PROSTVAC on tumor grade (Gleason score). VI. To assess the effect of PROSTVAC on tumor extent (percent of positive random biopsy cores). VII. To compare the proportion of men on the two study arms with no cancer on post-intervention biopsy. VIII. To assess the effect of PROSTVAC on the size of the dominant lesion on magnetic resonance imaging (MRI) (largest histopathologically confirmed lesion) in the subgroup of patients with MRIs pre and postintervention. IX. To assess the effect of PROSTVAC on circulating 15-Mer PSA-specific, MUC-1 and Brachyury-specific T cells. X. To assess the effect of PROSTVAC on soluble antibodies to tumor-associated antigens. XI. To assess the immunologic effects of PROSTVAC in prostate tissue using multiplex immunofluorescence. XII. To assess the safety and feasibility of PROSTVAC in the active surveillance population. XIII. To assess the effect of PROSTVAC on lower urinary tract symptoms (LUTS) in the active surveillance population. OUTLINE: Patients are randomized to 1 of 2 treatment arms. ARM I: Patients receive rilimogene-galvacirepvec subcutaneously (SC) at baseline and on days 14, 28, 56, 84, 112, and 140. ARM II: Patients receive placebo SC at baseline and on days 14, 28, 56, 84, 112, and 140. After completion of study treatment, patients are followed up for 30 days and then at 6 months.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 154
• Est. completion date: July 20, 2022
• Est. primary completion date: November 30, 2018
• Accepts healthy volunteers: No
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Biopsy-proven (consisting of >= 10 tissue cores) adenocarcinoma of the prostate with cancer present in at least one biopsy core, either random or targeted, in the most recent biopsy
• All prior biopsies must meet the following: =< 50% of the total number of random biopsy cores positive for cancer
• Gleason score =< (3+4)
• Clinical stage =< T2a by digital rectal exam (DRE)
• Biopsies performed at outside institutions should have Gleason score confirmed at the study site by a genitourinary (GU) pathologist to ensure eligibility
• Pre-intervention biopsy tissue (most proximal to enrollment) with sufficient tumor tissue to cut 5-10 unstained slides confirmed to be available upon request
• Screening serum PSA < 20 ng/mL; for men treated with 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride), PSA needs to be < 10 ng/mL
• Neutrophil count >= 1,200/mm^3 (>= 1.2 k/uL)
• Stable platelet count >= 75,000/mm^3 (>= 75 k/uL)
• Bilirubin =< 1.5 mg/dL (or =< 3.0 mg/dL for patients with Gilbert's syndrome)
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN)
• Serum creatinine =< 1.5 x ULN
• Karnofsky >= 70%
• Must agree to use medically acceptable barrier and/or chemical method of contraception while on study and for at least one month following the last vaccine injection; should a participant's partner become pregnant or suspect she is pregnant while the participant is participating in this study, the study physician should be informed immediately; in the event a participant's partner becomes pregnant, the study sponsor may request additional information regarding the course of the pregnancy and if the pregnancy is carried to term, the birth of the child (i.e., the outcome of the pregnancy)
• Ability to understand and the willingness to sign a written informed consent document
• No planned prostate biopsies during the intervention until after the post-intervention biopsy
• Men on stable doses of 5-alpha reductase inhibitors are eligible as long as there is no planned dose change while on study

Exclusion Criteria:

• Have had prior treatment for prostate cancer by surgery, irradiation, local ablative (i.e., cryosurgery or high-intensity focused ultrasound), or androgen-deprivation therapy
• Patients who have prostate cancer with distant metastases
• Have undergone treatment of hormone therapy, immunotherapy, chemotherapy and/or radiation for any malignancies within the past 2 years
• Uncontrolled intermittent illnesses or medical conditions which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient; such illnesses/conditions may include, but are not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Positive for human immunodeficiency virus (HIV) or active infections for hepatitis B, and/or hepatitis C, based on medical history
• Prior solid organ or bone marrow transplant
• Immunodeficiency or splenectomy
• Chronic immunosuppressive therapy within 30 days of screening
• Inflammatory eye disease requiring steroid treatment within 28 days of screening
• Chronic administration (defined as daily or every other day for continued use > 14 days) of systemic corticosteroids within 28 days of the first planned dose of PROSTVAC-V/F; use of inhaled steroids, nasal sprays, and topical creams for small body areas is allowed
• History of or active autoimmune disease including but not limited to autoimmune neutropenia, thrombocytopenia, or hemolytic anemia, systemic lupus erythematosus, Sjogren's syndrome, scleroderma, myasthenia gravis, Goodpasture's syndrome; persons with vitiligo are not excluded; Persons with well-controlled autoimmune endocrinopathies, e.g., diabetes mellitus, Graves' disease, Hashimoto's thyroiditis, Addison's disease are not excluded; persons with well-controlled rheumatoid arthritis, psoriatic arthritis and polymyalgia rheumatica are not excluded
• Known allergy to eggs, egg products
• Prior or concurrent eczema or other eczemoid skin disorders or active skin condition (acute, chronic, or exfoliative) that disrupts the epidermis; persons with psoriasis

are not excluded except in cases of:

• any active lesion
• any active lesion in the previous 6 months that required treatment, either systemic or topical
• any prior episode, at any time, extensive enough or severe enough as to require systemic treatment
• Previous adverse reactions to smallpox vaccination
• Unable to avoid close contact or household contact with the following high-risk individuals for three weeks after the day 1 vaccination or until the vaccination site heals completely: (a) children =< 3 years of age, (b) pregnant or nursing women, (c) individuals with prior or concurrent extensive eczema or other eczemoid skin disorders, (d) individuals with other acute, chronic, or exfoliative skin condition, or (e) immunocompromised or immunosuppressed persons (by disease or therapy)
• Participants may not be receiving any other investigational agents
• History of allergic reactions attributed to compounds of similar chemical or biologic composition of PROSTVAC

Related Conditions & MeSH terms

• Adenocarcinoma
• Prostatic Neoplasms
• Stage I Prostate Adenocarcinoma AJCC v7
• Stage II Prostate Adenocarcinoma AJCC v7

Intervention

Other:
• Laboratory Biomarker Analysis
Correlative studies
• Placebo Administration
Given SC

Biological:
• Rilimogene Galvacirepvec
Given SC

Locations

Country	Name	City	State
United States	Johns Hopkins Bayview Medical Center	Baltimore	Maryland
United States	NCI - Center for Cancer Research	Bethesda	Maryland
United States	Cedars Sinai Medical Center	Los Angeles	California
United States	USC / Norris Comprehensive Cancer Center	Los Angeles	California
United States	Hoag Memorial Hospital	Newport Beach	California
United States	UC Irvine Health/Chao Family Comprehensive Cancer Center	Orange	California
United States	UC San Diego Medical Center - Hillcrest	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in CD8+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies	change (from pre to post-intervention) in CD8+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies.	Baseline to up to 14 days after the last dose
Primary	Change in CD4+ Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies	change (from pre to post-intervention) in CD4+ positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies.	Baseline to up to 14 days after the last dose
Secondary	Change in PD-L1 Positive Cells in the Stroma Adjacent to Tumor and Within the Malignant Portion of the Prostate Biopsies	Change (from pre to post-intervention) in PD-L1 positive cells in the stroma adjacent to tumor and within the malignant portion of the prostate biopsies	Baseline to 6 months post-intervention
Secondary	Change in Prostate-specific Antigen (PSA)	Change (from baseline to 6 months post-intervention) in prostate-specific antigen (PSA)	Baseline to 6 months post-intervention
Secondary	Change in CD8+ Positive Cells in the Benign Portion of the Prostate Biopsies	Change (from pre to post-intervention) in CD8+ positive cells in the benign portion of the prostate biopsies	Baseline to up to 14 days after the last dose
Secondary	Change in CD4+ Positive Cells in the Benign Portion of the Prostate Biopsies	Change (from pre to post-intervention) in CD4+ positive cells in the benign portion of the prostate biopsies	Baseline to up to 14 days after the last dose
Secondary	Change in PD-L1 Positive Cells in the Benign Portion of the Prostate Biopsies	Change (from pre to post-intervention) in PD-L1 positive cells in the benign portion of the prostate biopsies	Baseline to up to 14 days after the last dose
Secondary	Tumor Grade Progression	Assessed by the proportion of men with an increase in Gleason score to >= 4+3 from baseline to post-intervention biopsy. The Gleason score is determined by adding the two most common grades. The Gleason score usually ranges from 6 to 10. Higher numbers indicate a faster growing cancer that is more likely to spread.	Baseline to up to 14 days after the last dose
Secondary	Change in Tumor Extent	Assessed by change (from pre to post-intervention) in percent positive random cores	Baseline to up to 14 days after the last dose
Secondary	Proportion of Men With no Cancer in the Post-intervention Biopsy	Assessed by the proportion of patients with no cancer on the post-intervention biopsy	Up to 14 days after the last dose
Secondary	Size of Dominant MRI Lesion	The size of dominant MRI lesion.	Up to 14 days after the last dose
Secondary	Change in Circulating 15-Mer PSA-specific T Cells	Change (from pre to post-intervention) in circulating 15-Mer PSA-specific T cells	Baseline to up to 14 days after the last dose
Secondary	Change in Soluble Antibodies to Tumor-associated Antigens	Change (from pre to post-intervention) in soluble antibodies to tumor-associated antigens	Baseline to up to 14 days after the last dose
Secondary	Immunologic Effects on the Target Organ Using Multiplex Immunofluorescence		Up to 14 days after the last dose
Secondary	Change in International Prostate Symptom Score	Change (from baseline to 6 months post-intervention) in International Prostate Symptom Score (IPSS). The IPSS score ranges from 0-35. Higher scores mean a worse symptom.	Baseline to up to 6 months post-intervention